Several other research firms have also recently weighed in on CYDY. Zacks Investment Research cut shares of CytoDyn from a buy rating to a hold rating in a research note on Monday, November 18th. HC Wainwright reaffirmed a buy rating and set a $1.50 target price (up from $1.00) on shares of CytoDyn in a research note on Thursday, December 19th.
Shares of OTCMKTS CYDY opened at $1.03 on Tuesday. The firm has a fifty day moving average price of $0.64 and a 200-day moving average price of $0.45. The stock has a market cap of $436.68 million, a PE ratio of -4.90 and a beta of 1.15. CytoDyn has a 1 year low of $0.06 and a 1 year high of $1.18.
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Further Reading: Hedge Funds Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.